Prudential Financial Inc. Has $3.45 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Prudential Financial Inc. increased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 111.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 104,922 shares of the biopharmaceutical company's stock after buying an additional 55,400 shares during the period. Prudential Financial Inc. owned 0.18% of Agios Pharmaceuticals worth $3,448,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. KBC Group NV lifted its position in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company's stock worth $539,000 after purchasing an additional 688 shares during the period. Atria Investments Inc lifted its holdings in Agios Pharmaceuticals by 6.9% during the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock worth $373,000 after purchasing an additional 737 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals in the 4th quarter valued at $33,000. Finally, Swiss National Bank grew its holdings in Agios Pharmaceuticals by 1.0% in the 4th quarter. Swiss National Bank now owns 100,760 shares of the biopharmaceutical company's stock valued at $3,311,000 after buying an additional 1,000 shares in the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AGIO. Royal Bank of Canada lifted their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective for the company. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. StockNews.com downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. Finally, Scotiabank increased their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of "Hold" and an average target price of $56.57.

Agios Pharmaceuticals Stock Down 7.0 %

Shares of AGIO stock traded down $1.95 during trading hours on Friday, reaching $25.76. The company's stock had a trading volume of 1,192,473 shares, compared to its average volume of 709,084. Agios Pharmaceuticals, Inc. has a fifty-two week low of $25.26 and a fifty-two week high of $62.58. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of 2.27 and a beta of 0.83. The firm's 50 day simple moving average is $32.55 and its 200-day simple moving average is $40.19.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.93% of the stock is currently owned by insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.